ViewPoint Therapeutics

ViewPoint Therapeutics is a biotechnology company founded in 2014 with a focus on developing treatments for diseases caused by protein misfolding, such as cataracts. The company's crystallin stabilizers include a small molecule that has shown activity in preclinical models of age-related cataracts through a target-based screening and optimization effort. This approach aims to provide physicians with medications to prevent or reverse protein misfolding, addressing numerous common disorders of aging, including cataracts, presbyopia, and neurodegenerative diseases. The company has recently received a significant $35.00M Series B investment at 05 March 2018 from a group of prominent investors including Mission Bay Capital, The Rise Fund, BVF Partners, Mission BioCapital, Novo Ventures, and Lagunita BioSciences LLC. This infusion of capital signifies a significant level of confidence in ViewPoint Therapeutics' innovative approach and potential to make a meaningful impact in the realm of biotechnology and healthcare. With a focus on addressing prevalent age-related disorders, the company's efforts align with the growing demand for effective treatments in the healthcare industry.